Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.
News|Articles|September 17, 2026
End-to-End Commercialization Guide
Author(s)Envision Pharma
Two Labs and Riparian, both part of Envision Pharma Group, work alongside specialty pharma manufacturers at nearly every stage of commercialization — government pricing and compliance, patient support programs, specialty pharmacy selection, trade and distribution, and post-launch optimization. Each chapter of this guide was written by the experts who lead that work, drawing on real conversations with manufacturers navigating these decisions.
Advertisement
What's Inside
- How pricing pressure, the IRA, and drug price transparency laws are reshaping commercial strategy
- Why patient support has become a commercial imperative, not an operational function
- How to select and implement a specialty pharmacy partner before launch
- Where post-launch optimization breaks down — and how to connect strategy to performance
- Insights from Two Labs and Riparian experts across every stage of commercialization
- PLUS: A Pre-Launch Readiness Assessment: Click here to take it
Advertisement
Related to this article
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.
EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
What DOL’s Final PBM Rule Means for Rebates and Formularies
2
Large Pharma vs. Emerging Biotech: Two Launch Playbooks
3
FAQ: How DOL’s PBM Disclosure Rule Reaches Drugmaker Contracts
4
Pharma Pulse: GoodRx Opens Employer GLP-1 Channel, Lilly Fends Off Novo Ad Challenge, PCMA Takes Aim at Wholesalers
5